



## **ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019**

**Geneva, Switzerland and Boston, MA –December 6, 2019** - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that it will release results from the Phase 3 PRIMROSE 2 clinical trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids, on Monday December 9, 2019. ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, Monday December 9, 2019, to discuss these results.

Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers, and referring to conference ID 1764134. A webcast of the conference call can be accessed under the "Investors" section of ObsEva's website [www.obseva.com](http://www.obseva.com).

### **About ObsEva**

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol "OBSN". For more information, please visit [www.ObsEva.com](http://www.ObsEva.com).

**For further information, please contact:**

#### **Media Contact Switzerland and Europe:**

Christophe Lamps

Dynamics Group

[cla@dynamicsgroup.ch](mailto:cla@dynamicsgroup.ch)

+41 22 308 6220 Office

+41 79 476 26 87 Mobile

**Media Contact U.S.:**

Marion Janic

RooneyPartners LLC

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)

+1 212 223 4017 Office

+1 646 537 5649 Mobile

**CEO Office Contact:**

Shauna Dillon

[Shauna.dillon@obseva.ch](mailto:Shauna.dillon@obseva.ch)

+41 22 552 1550

**Investor Contact:**

Mario Corso

Senior Director, Investor Relations

[mario.corso@obseva.com](mailto:mario.corso@obseva.com)

+1 857 972 9347 Office

+1 781 366 5726 Mobile